Ulcerative Colitis PBMC

Ulcerative Colitis PBMC for Immune-Mediated Intestinal Inflammation Research

Human Ulcerative Colitis PBMC are sourced from IRB-consented donors clinically diagnosed with ulcerative colitis, processed within 24 hours of collection and cryopreserved in CryoStor® CS10. Ulcerative colitis is an immune-mediated inflammatory bowel disease, not a classical autoantibody-driven autoimmune condition: a genetically susceptible host mounts a dysregulated mucosal immune response to the commensal gut microbiota behind a compromised epithelial barrier. These cryopreserved peripheral blood mononuclear cells support work on the circulating arm of that response.

Why PBMC for Ulcerative Colitis

Ulcerative colitis inflammation is confined to the colonic mucosa and extends continuously from the rectum, but the lymphocytes that populate that mucosa are recruited from blood. Peripheral cells therefore carry the imprint — and the drug targets — of intestinal disease.

• Gut-homing lymphocytes are measurable in blood — circulating T cells expressing the alpha-4-beta-7 integrin and CCR9 are the population that traffics to intestinal tissue, and they are the direct target of anti-integrin therapy. PBMC allow receptor occupancy and phenotype to be assessed without endoscopy.
• Cytokine pathways match approved drug classes — TNF, the IL-12/IL-23 axis and JAK-STAT signalling are all validated targets in ulcerative colitis, and each can be interrogated ex vivo in intact PBMC through stimulation and phospho-signalling assays.
• Microbial antigen responsiveness — because the disease reflects loss of tolerance to commensal flora, PBMC recall responses to bacterial antigens and to flagellin-type antigens are a mechanistically meaningful readout.
• Loss of response and immunogenicity — a substantial fraction of patients lose response to biologics. Paired PBMC and treatment annotation support research into anti-drug antibody formation and cellular resistance mechanisms.
• Distinguishing UC from Crohn’s disease biology — a colon-restricted, continuous, mucosa-limited disease behaves differently from transmural, patchy small-bowel disease; UC-specific PBMC avoid blending the two.
• Single-cell resolution of rare subsets — regulatory T cells, innate lymphoid cells and monocyte subsets in the circulation are best resolved by single-cell approaches on viable, well-preserved PBMC.

Donor Stratification Available

• Disease activity: active flare versus clinical or endoscopic remission; Mayo or endoscopic Mayo score where recorded
• Disease extent: ulcerative proctitis, left-sided colitis, or extensive colitis/pancolitis
• Treatment status: treatment-naive, 5-aminosalicylate, corticosteroid, thiopurine, anti-TNF, anti-integrin, anti-IL-12/23, JAK inhibitor, or S1P modulator
• Biologic response category: primary non-responder, responder, or secondary loss of response where documented
• Surgical history including prior colectomy or ileal pouch, and disease duration
• Extraintestinal manifestations, including primary sclerosing cholangitis and inflammatory arthritis
• Matched healthy controls available, age- and sex-matched on request

Product Features

• Research Use Only (RUO), cryopreserved PBMCs
• Clinically confirmed ulcerative colitis donors
• Available in cell counts ranging from 5 million to 2 billion
• Processed within 24 hours of collection
• Stored using CryoStor® CS10 freezing media
• Viability and recovery reported per lot
• IRB-approved protocols and electronic informed consent
• Screen LeukoLot™ available prior to bulk orders

De-identified Donor Data

• Verified ulcerative colitis diagnosis
• Donor demographics: age, sex assigned at birth, race/ethnicity
• Self-reported allergies, medications and infectious disease history
• Disease extent, activity scores and treatment history where recorded
• Additional ulcerative colitis-specific data available upon request

Applications

• Immunophenotyping of gut-homing alpha-4-beta-7 and CCR9 positive T cells
• Ex vivo cytokine stimulation and JAK-STAT phospho-signalling assays
• Anti-integrin and anti-cytokine mechanism-of-action and receptor occupancy research
• Microbial antigen recall response studies
• Loss-of-response and anti-drug antibody research
• Single-cell RNA-seq and CITE-seq of the circulating IBD immune compartment
• Transcriptomic and proteomic profiling for biomarker discovery
• Drug screening and therapeutic development in inflammatory bowel disease

Other Ulcerative Colitis Specimen Types

• Ulcerative Colitis Serum
• Ulcerative Colitis Plasma
• Ulcerative Colitis Whole Blood
• Ulcerative Colitis Leukopak
• Ulcerative Colitis CD4+ T Cells
• Inflammatory Bowel Disease PBMC

Compliance and Quality Assurance

• IRB-approved collections and protocols
• 21 CFR Part 11 – compliant e-consent system
• HIPAA-compliant donor data protection

Ordering & Customization

Ulcerative Colitis PBMC samples are shipped on dry ice and available in custom aliquots. For pricing, availability or a specific stratification request, email learnmore@sanguinebio.com; please also contact us for international orders or regulatory documentation needs. To browse availability across all disease states, visit our human PBMC page.